According to MannKind Corp's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 5.55238. At the end of 2023 the company had a P/S ratio of 4.93.
Year | P/S ratio | Change |
---|---|---|
2023 | 4.93 | -64.53% |
2022 | 13.9 | -4.48% |
2021 | 14.6 | 28.53% |
2020 | 11.3 | 161.27% |
2019 | 4.33 | -39.1% |
2018 | 7.12 | -69.69% |
2017 | 23.5 | 1247.23% |
2016 | 1.74 | |
2015 | N/A | |
2014 | N/A | |
2013 | N/A | -100% |
2012 | > 1000 | 187.47% |
2011 | > 1000 | -40.71% |
2010 | > 1000 | |
2009 | N/A | -100% |
2008 | > 1000 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Pfizer PFE | 2.46 | -55.74% | ๐บ๐ธ USA |
Novo Nordisk NVO | 16.2 | 191.70% | ๐ฉ๐ฐ Denmark |
Eli Lilly LLY | 20.8 | 274.32% | ๐บ๐ธ USA |
Merck MRK | 5.28 | -4.96% | ๐บ๐ธ USA |
Halozyme Therapeutics HALO | 5.79 | 4.33% | ๐บ๐ธ USA |
Nektar Therapeutics
NKTR | 2.69 | -51.56% | ๐บ๐ธ USA |